Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy

QR Code

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy

Dietmar Schnober,1 Douglas A Hubatsch,2 Maria-Luise Scherzer3 1Private Ophthalmology Practice, Werdohl, Germany; 2Alcon Laboratories, Inc., Fort Worth, TX, USA; 3Private Ophthalmology Practice, Regenstauf, Germany Purpose: To determine the efficacy and safety of fixed-combination travoprost 0.004%...

Full description

Saved in:

Bibliographic Details
Main Authors:	Schnober D, Hubatsch DA, Scherzer ML
Format:	article
Language:	EN
Published:	Dove Medical Press 2015
Subjects:	Ophthalmology RE1-994
Online Access:	https://doaj.org/article/9808f3ef76cb44d89a62782936cf2bc7
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
by: Moataz E Gheith, et al.
Published: (2008)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
by: Pfennigsdorf S, et al.
Published: (2016)

Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy
by: Costa VP, et al.
Published: (2012)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
by: Douglas J Rhee, et al.
Published: (2008)

Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
by: Kozobolis V, et al.
Published: (2018)

Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from &szlig;-blockers and prostaglandin analogs
by: Inoue K, et al.
Published: (2012)

Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
by: Inoue K, et al.
Published: (2015)

Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure
by: Anne J Lee, et al.
Published: (2008)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
by: Kanamoto T, et al.
Published: (2012)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
by: Baiza-Dur&aacute;n LM, et al.
Published: (2012)

Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
by: Shimizu Y, et al.
Published: (2015)

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy
by: Inoue K, et al.
Published: (2012)

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg
by: Yelda Buyru &Ouml;zkurt, et al.
Published: (2009)

Efficacy and safety of switching to latanoprost 0.005%–timolol maleate 0.5% fixed-combination eyedrops from an unfixed combination for 36 months
by: Inoue K, et al.
Published: (2014)

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
by: Abayomi B Ogundele, et al.
Published: (2010)

Effect of 3 years of treatment with a dorzolamide/timolol (1%/0.5%) combination on intraocular pressure
by: Takeda S, et al.
Published: (2014)

Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily
by: Moisseiev E, et al.
Published: (2013)

Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension
by: Lorenz K, et al.
Published: (2011)

First experience with BAK-free travoprost 0.004% in topical glaucoma medication
by: Gado AS, et al.
Published: (2011)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
by: Chang-Lin J-E, et al.
Published: (2011)

Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination
by: Inoue K, et al.
Published: (2012)

Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
by: Nicholas P Bell, et al.
Published: (2010)

Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%
by: Dubiner HB, et al.
Published: (2012)

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
by: Mizoguchi T, et al.
Published: (2012)

Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions
by: Campbell JH, et al.
Published: (2014)

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study
by: Pillunat LE, et al.
Published: (2017)

Efficacy and safety of 0.5% levobupivacaine versus 0.5% bupivacaine for peribulbar anesthesia
by: Pacella E, et al.
Published: (2013)

Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day
by: Moisseiev E,&nbsp;Lazar M, et al.
Published: (2012)

Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension
by: Henny JM Beckers, et al.
Published: (2009)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
by: Michael J Miyashiro, et al.
Published: (2010)

Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops
by: Rosin LM, et al.
Published: (2013)

Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma
by: Mizoguchi T, et al.
Published: (2011)

Preparation and characterization of a new graphite superconductor: Ca0.5Sr0.5C6
by: Saki Nishiyama, et al.
Published: (2017)

Light-induced enhancement of superconductivity in iron-based superconductor FeSe0.5Te0.5
by: Kazuki Isoyama, et al.
Published: (2021)

Li(V0.5Ti0.5)S2 as a 1 V lithium intercalation electrode
by: Steve J. Clark, et al.
Published: (2016)

Magnetic breakdown in 2D hole system at GaAs/Al0.5Ga0.5As heterointerface
by: Minina, N., et al.
Published: (2005)

Photoconductivity in p-GaAs/Al0.5Ga0.5As and deep donor like states at heterointerface
by: Bogdanov, E., et al.
Published: (2005)

Efficacy Evaluation of 755-nm Long-Pulse Alexandrite Laser Combined with 0.5% Timolol Maleate Eye Drops in the Treatment of Thicker Infantile Hemangioma
by: Wu J, et al.
Published: (2021)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
by: David A Godfrey, et al.
Published: (2009)

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
by: Inoue K, et al.
Published: (2014)